Anne Rebecca Evans

US Patent:

8394354, Mar 12, 2013

Filed:

May 8, 2007

Appl. No.:

12/300000

Inventors:

Lisa A. Paige - Hillsborough NC, US
Matthew W. Mitchell - Durham NC, US
Anne Evans - Durham NC, US
Don Harvan - Durham NC, US
David Carl Steffens - Durham NC, US
K. Ranga R. Krishnan - Chapel Hill NC, US

Assignee:

Metabolon, Inc. - Durham NC
Duke University - Durham NC

International Classification:

G01N 33/49
G01N 33/50
G01N 33/64

US Classification:

424 91, 702 19, 702 23

Abstract:

The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.

US Patent:

20070298998, Dec 27, 2007

Filed:

Feb 27, 2007

Appl. No.:

11/711518

Inventors:

Lisa Paige - Hillsborough NC, US
Matthew Mitchell - Durham NC, US
Anne Evans - Durham NC, US
Don Harvan - Durham NC, US
Kay Lawton - Raleigh NC, US
Robert Brown - Needham MA, US
Merit Cudkowicz - Newton MA, US

Assignee:

Metabolon, Inc. - Durham NC

International Classification:

A61K 38/00
A61P 25/28
G01N 30/02

US Classification:

514002000, 436161000

Abstract:

The present invention provides various biomarkers of amyotrophic lateral sclerosis (ALS). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of ALS, methods of determining predisposition to ALS, methods of monitoring progression/regression of ALS, methods of assessing efficacy of compositions for treating ALS, methods of screening compositions for activity in modulating biomarkers of ALS, methods of treating ALS, as well as other methods based on biomarkers of ALS.

US Patent:

20080153112, Jun 26, 2008

Filed:

May 20, 2004

Appl. No.:

10/557273

Inventors:

Teresa P. DiLorenzo - Bayside NY, US
Anne M. Evans - Chapel Hill NC, US
Donald F. Hunt - Charlottesville VA, US
Scott M. Lieberman - Bronx NY, US
Stanley G. Nathenson - Pelham Manor NY, US
Pere Santamaria - Calgary CA, US
Jeffrey Shabanowitz - Charlottesville VA, US

International Classification:

A61K 31/711
A61K 38/08
A61P 3/10
C07H 21/02
C07H 21/04
C07K 14/00
C07K 7/00
C12N 5/06
G01N 33/567

US Classification:

435 721, 435375, 514 15, 514 16, 514 44, 530324, 530326, 530327, 530328, 530350, 536 231, 536 245

Abstract:

The present invention is based on the identification of a predominant ligand of CD8+ T cells that are responsible eq for type diabetes. That ligand is islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). Several CD8+ T cell-binding peptides from IGRP are identified, including the peptide comprising amino acids 206-214 of the IGRP sequence, which has high avidity to the most prevalent T cell receptor of pathogenic CD8+ T cells in autoimmune diabetes. The invention thus provides oligopeptide and polypeptide compositions comprising YLKTN/A/I/L/V)FL, FLWSVFWLI, (T/A)YY/G/T)FLNFM, LR(LV)(F/L)(G/N)IDLL, KWCANPDWI, and SFCKSASIP. Also provided are oligopeptide compositions 8-10 amino acids in length and completely homologous with a mammalian IGRP, where the oligopeptide is capable of binding a human MHC class I molecule. Additionally, various methods of treating a mammal using the above compositions are provided, where the mammal is at risk for or has type 1 diabetes. Also provided are methods of preventing a CD8+ T cell that is cytotoxic to pancreatic islet β-cells from destroying a mammalian β-cell, where the methods also use the above compositions. Further provided are methods for determining whether a mammal is at risk for or has type 1 diabetes, where the methods use the above compositions.

US Patent:

20090318369, Dec 24, 2009

Filed:

Aug 15, 2008

Appl. No.:

12/192469

Inventors:

Lisa A. Paige - Hillsborough NC, US
Matthew W. Mitchell - Durham NC, US
Anne Evans - Durham NC, US
Don Harvan - Durham NC, US

International Classification:

A61K 31/70
G01N 33/50
G01N 33/92
G01N 33/53
C12Q 1/02
G01N 33/68
A61K 31/195
A61K 31/56
A61K 31/19
A61K 31/415
A61K 31/52
A61K 31/66
A61P 25/28

US Classification:

514 23, 436111, 436 71, 436129, 436 96, 436 98, 436 93, 436103, 436 94, 435 792, 435 29, 436 86, 514563, 514182, 514557, 514396, 5142631, 514 75

Abstract:

The present invention provides various biomarkers of Alzheimer's Disease (AD). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of AD, methods of determining predisposition to AD, methods of monitoring progression/regression of AD, methods of assessing efficacy of compositions for treating AD, methods of screening compositions for activity in modulating biomarkers of AD, methods of treating AD, as well as other methods based on biomarkers of AD.